NUVECTIS PHARMA INC (NVCT)
Health Care · Oncology kinase inhibitors · NASDAQ
Nuvectis is an early-stage oncology biotech developing NXP900, a novel SRC/YES1 kinase inhibitor designed to overcome drug resistance in solid tumors including breast, lung, prostate, and pancreatic cancers.
What NUVECTIS PHARMA INC does
Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicine oncology treatments. The company's lead candidate, NXP900, is a SRC/YES1 kinase inhibitor targeting solid tumors with SRC/YES1 activation, currently in Phase 1b clinical trials both as a single agent and in combination with EGFR and ALK inhibitors. The company has generated no revenue to date and focuses on research, development, and clinical advancement of its drug pipeline.
Themes: ["SRC/YES1 kinase inhibition","oncology precision medicine","solid tumors","drug resistance reversal","kinase inhibitor combinations"]
Fundamentals
- Price$18.99 as of 2026-07-09 close
- Market cap$599M as of 2026-07-10
- 1-year return+147.4% as of 2026-07-09 close
- ROE-147.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta-0.23 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: NXP900 is still in Phase 1b with uncertain efficacy and safety outcomes, with no approved kinase inhibitor to date for SRC-active solid tumors","No revenue generation to date: the company is pre-commercial and dependent on continued capital funding to support clinical trials and operations","Competitive pressure: other pharmaceutical companies may develop competing SRC/YES1 inhibitors or alternative therapies for the same oncology indications"]
Competitors & peers
- Boehringer Ingelheim
- Bristol Myers Squibb
- Eli Lilly
- Merck
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.